mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses.
van den Dijssel J, Duurland MC, Konijn VA, Kummer LY, Hagen RR, Kuijper LH, Wieske L, van Dam KP, Stalman EW, Steenhuis M, Geerdes DM, Mok JY, Kragten AH, Menage C, Koets L, Veldhuisen B, Verstegen NJ, van der Schoot CE, van Esch WJ, D'Haens GR, Löwenberg M, Volkers AG, Rispens T, Kuijpers TW, Eftimov F, van Gisbergen KP, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group.
van den Dijssel J, et al. Among authors: van der schoot ce.
J Autoimmun. 2024 Apr;144:103175. doi: 10.1016/j.jaut.2024.103175. Epub 2024 Feb 21.
J Autoimmun. 2024.
PMID: 38387105
Free article.